• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time

    7/10/24 6:09:53 PM ET
    $AGCO
    $AMTX
    $BCPC
    $CSL
    Industrial Machinery/Components
    Industrials
    Major Chemicals
    Industrials
    Get the next $AGCO alert in real time by email

    Avian influenza, also known as bird flu, has public health officials on alert after it spread to an unprecedented number of cows in the U.S. this year and led to positive tests of the virus in four U.S. dairy workers so far this year.

    A severe variant of the H5N1 strain infected animals ranging from alpacas to house cats worldwide since 2020 and caused lethal outbreaks in commercial poultry, but this is the first year it has infected cows, Reuters reported.

    Humans have contracted different bird flu strains in Australia and Mexico, while different H5 subtypes have also shown up in other parts of the world including China and Cambodia.

    Most of the human cases have come from exposure to poultry, live poultry markets and dairy cattle, but scientists worry the virus could mutate so it could easily spread between humans and spark a pandemic. The World Health Organization says the risk to people is low at this point, Reuters reported.

    The first known bird flu cases happened in Texas in March, and now the virus has infected dairy herds in 12 states. The U.S. Agriculture Department said tests so far reveal that the virus detected in cows is the same H5N1 virus affecting wild birds and commercial poultry flocks.

    Also Read: First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map

    The four dairy workers who have tested positive for the virus this year had mild symptoms such as conjunctivitis, or pink eye.

    Michigan, which has two of the four cases infecting dairy workers, has led the nation in efforts to stop the spread of bird flu and prevent negative impacts to the state’s dairy industry.

    State restrictions include tracking who comes and goes from farms as Michigan tests more people than any of the 12 states with confirmed cases in cows, according to a Reuters survey of state health departments.

    So far this year, various forms of bird flu have been detected in 21 people worldwide, according to Reuters.

    Price Action: Most companies busy developing bird-flu vaccines saw gains on Wednesday. Moderna, Inc. (NASDAQ:MRNA) picked up 1.18% to close at $117.44, while GSK plc (NYSE:GSK) slipped 0.12% to $38.56 and Carlisle Companies Inc. (NYSE:CSL) gained 2.28% to $416.88.

    Dairy stocks and agriculture and dairy cattle exchange-traded funds gave mixed reactions. AGCO Corp (NYSE:AGCO) gained 0.69% to close at $94.21 on Wednesday as Aemetis, Inc. (NASDAQ:AMTX) declined 3.18% to $3.35 and Balchem Corp (NASDAQ:BCPC) picked up 0.60% to $162.89.

    Invesco DB Agriculture Fund (NYSE:DBA) declined 1.23% on Wednesday to $1.23, while First Trust Dow Jones Select MicroCap Index Fund (NYSE:FDM) rose 1.71% to $59.51 and Invesco S&P SmallCap 600 Pure Value ETF (NYSE:RZV) improved 1.32% to $98.

    Read Now:

    • Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures

    Photo: Shutterstock

    Get the next $AGCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGCO
    $AMTX
    $BCPC
    $CSL

    CompanyDatePrice TargetRatingAnalyst
    Carlisle Companies Incorporated
    $CSL
    1/30/2026Mkt Perform
    William Blair
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    GSK plc
    $GSK
    1/27/2026Neutral
    Citigroup
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    GSK plc
    $GSK
    1/6/2026Equal Weight → Underweight
    Barclays
    AGCO Corporation
    $AGCO
    12/19/2025$93.00Equal Weight → Underweight
    Barclays
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Balchem Corporation
    $BCPC
    12/5/2025$162.00Neutral
    Rothschild & Co Redburn
    More analyst ratings

    $AGCO
    $AMTX
    $BCPC
    $CSL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Hoge Stephen exercised 160,009 shares at a strike of $19.15 and sold $7,814,840 worth of shares (160,009 units at $48.84) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    2/25/26 4:49:00 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VP & Chief Accounting Officer Easton Andrew C exercised 300 shares at a strike of $150.00 and sold $94,964 worth of shares (233 units at $407.57), increasing direct ownership by 8% to 926 units (SEC Form 4)

    4 - CARLISLE COMPANIES INC (0000790051) (Issuer)

    2/19/26 4:18:25 PM ET
    $CSL
    Specialty Chemicals
    Industrials

    SVP GM Fendt/Valtra Dehner Torsten Rudolf Willi exercised 5,100 shares at a strike of $72.74 and covered exercise/tax liability with 3,436 shares, increasing direct ownership by 4% to 46,982 units (SEC Form 4)

    4 - AGCO CORP /DE (0000880266) (Issuer)

    2/18/26 5:10:49 PM ET
    $AGCO
    Industrial Machinery/Components
    Industrials

    $AGCO
    $AMTX
    $BCPC
    $CSL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director De Lange Bob bought $250,382 worth of shares (2,642 units at $94.77), increasing direct ownership by 20% to 16,003 units (SEC Form 4)

    4 - AGCO CORP /DE (0000880266) (Issuer)

    5/7/25 2:13:24 PM ET
    $AGCO
    Industrial Machinery/Components
    Industrials

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGCO
    $AMTX
    $BCPC
    $CSL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGCO
    $AMTX
    $BCPC
    $CSL
    SEC Filings

    View All

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    2/27/26 7:17:44 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    2/26/26 6:57:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    2/26/26 6:50:06 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGCO
    $AMTX
    $BCPC
    $CSL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Balchem Corporation to Participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026

    MONTVALE, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the

    2/25/26 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026

    MONTVALE, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest

    2/24/26 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGCO
    $AMTX
    $BCPC
    $CSL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Carlisle Cos

    William Blair initiated coverage of Carlisle Cos with a rating of Mkt Perform

    1/30/26 6:58:54 AM ET
    $CSL
    Specialty Chemicals
    Industrials

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on GlaxoSmithKline

    Citigroup initiated coverage of GlaxoSmithKline with a rating of Neutral

    1/27/26 8:46:26 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGCO
    $AMTX
    $BCPC
    $CSL
    Financials

    Live finance-specific insights

    View All

    Balchem Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    MONTVALE, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal fourth quarter and full year ended December 31, 2025. For the quarter, the Company reported net sales of $263.6 million, net earnings of $39.2 million, adjusted EBITDA(a) of $67.9 million, and free cash flow(a) of $51.2 million. For the full year 2025, the Company reported net sales of $1.037 billion, net earnings of $154.8 million, adjusted EBITDA of $274.9 million, and free cash flow of $173.6 million. Ted Harris, Chairman, President, and CEO of Balchem said, "In the fourth quarter, Balchem's strong growth trajectory continued. We delivered record fo

    2/20/26 7:12:32 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2025 Financial Results on February 20, 2026

    MONTVALE, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 20, 2026, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year 2025 results will be published prior to the market opening on Friday, February 20, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial commu

    2/6/26 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    AGCO REPORTS FOURTH QUARTER AND 2025 FULL YEAR RESULTS

    Net sales of $10.1 billion, down 13.5%, in 2025Full year reported operating margin of 5.9% and adjusted operating margin(1) of 7.7%2025 full year reported earnings per share of $9.75 and adjusted earnings per share(1) of $5.28Cash flow provided by operating activities of $988 million and record free cash flow(1) of $740 million2026 net sales and earnings per share outlook above 2025 levelsDULUTH, Ga., Feb. 5, 2026 /PRNewswire/ -- AGCO (NYSE:AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, reported net sales of $2.9 billion for the fourth quarter of 2025, an increase of 1.1% compared to the fourth quarter of 2024. The fo

    2/5/26 7:30:00 AM ET
    $AGCO
    Industrial Machinery/Components
    Industrials

    $AGCO
    $AMTX
    $BCPC
    $CSL
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) is pleased to announce that, effective November 3, 2025, Jason Taylor will join the company as President of its Construction Materials business (CCM). As part of this transition, Steve Schwar will assume the role of Vice Chair of CCM to ensure a smooth and effective leadership transition. Both Mr. Taylor and Mr. Schwar will report to Chris Koch, Carlisle's Chair, President, and Chief Executive Officer. Mr. Taylor has joined CCM after more than 14 years at Beacon Building Products, now known as QXO, Inc., a leading distributor of roofing and complementary building products. At Beacon, Mr. Taylor held several key leadership roles, including most re

    11/3/25 9:00:00 AM ET
    $CSL
    Specialty Chemicals
    Industrials

    AGCO Names New PTx Leader to Accelerate Smart Farming Solutions and Growth

    DULUTH, Ga., Aug. 12, 2025 /PRNewswire/ -- AGCO (NYSE:AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, announced the appointment of Brian Sorbe as President of PTx, effective August 25, 2025. With nearly three decades of experience in precision agriculture, global sales and product development, Sorbe brings a wealth of expertise to this pivotal role. "I am thrilled to welcome Brian to the AGCO team as the leader of our exciting PTx technology portfolio," said Eric Hansotia, Chairman, President and CEO. "H

    8/12/25 8:05:00 AM ET
    $AGCO
    Industrial Machinery/Components
    Industrials

    $AGCO
    $AMTX
    $BCPC
    $CSL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AGCO Corporation

    SC 13D/A - AGCO CORP /DE (0000880266) (Subject)

    11/25/24 7:00:13 AM ET
    $AGCO
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by Balchem Corporation

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    11/13/24 6:56:07 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by GSK plc

    SC 13G/A - GSK plc (0001131399) (Subject)

    11/12/24 4:32:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care